PhenoPath
Diagnoses you can count on®

FISH

PhenoPath offers a comprehensive menu of state-of-the-art diagnostic, prognostic and therapy-directing fluorescence in situ hybridization (FISH) assays to aid in the diagnosis of a broad range of clinical settings. For information on specific tests or antibodies, please visit our website, email us at lab@phenopath.com, or contact Client Services or your Regional Sales Manager (888-927-4366).

PhenoPath is committed to rigorous testing, definitive diagnosis, and outstanding customer service, with an emphasis on accuracy, integrity, innovation, and accessibility to clients. Our testing strategies are based on continuous review of the most current medical literature, including the results of major clinical trials.

Features / Benefits

- Computer-aided image analysis increases sensitivity and accuracy of quantitative and qualitative analysis of genetic alterations
- Assays are optimized for small sample size and maximum FISH signal strength, aiding interpretation
- Every test reviewed and signed out by an experienced board-certified pathologist
- Pathologists & technologists available to address your clinical & technical questions
- Findings are correlated with histologic, immunophenotypic, molecular & clinical findings
- Rigorous test validation and quality control
- Rapid turnaround time: Test results typically reported within 3-4 business days of receipt
- Tests run 5 days/week

Specialized Consultative Services

- Prognostic and predictive markers
- Breast HER2 testing with detailed chromosome 17 evaluation for "polysomy"
- Hydatidiform mole evaluation (FISH & IHC)
- Hematolymphoid diagnosis, prognosis and subtyping
  - B Cell Neoplasms
  - Myeloid Neoplasms
- Small, blue, round cell tumors of childhood
- Spindle cell sarcoma/tumor subtyping
- "Floater" analysis by X/Y genotyping
- Validation services

PhenoPath
Diagnoses you can count on®

Test Menu – FISH

Our collection of available probes continues to expand. Please contact us if there is a probe you are unable to locate.

Test Name	Alternate Names / Panel Components	Fresh	Paraffin
1p36/19q13 - Oligodendroglioma	1p36/1q25 and 19q13/19p13		X
1q21+1p21*		X	
7q31 / del 7q*	7q31/CEP7	X	
11q22.3 (ATM)*		X	
11q23 MLL breakapart*	MLL (11q23); t(11q23) MLL	X	
13q14_D13S25*		X	
17p13.1_P53*		X	
20q12*		X	
ALK (2P23) translocations	ALK-IVD; ALK-ASR; EML4-ALK		X
AML (Acute Myelogenous Leukemia) panel*	Components: 7q31 / del 7q; 11q23 MLL (Breakapart); CEP8 (Trisomy 8); EGR1 (5q31/5p15.5); inv16 / t(16;16)(p13;q22) (CBFB); t(8;21)(RUNX1/RUNX1T1) - t(15;17) (PML/RARA)	X	
APL (Acute Promyelocytic Leukemia) panel*	Components: t(15;17) PML/RARA; RARA translocations	X	
BCL6 translocations*	BCL6 (3q27)	X	X
CEP-X/Y			X
CEP5*	CEP5 (D5S23, D5S721)	X	
CEP7*	CEP7 (7p11.1-q11.1)	X	
CEP8 (Trisomy 8)*		X	
CEP11*	CEP11 (11p11.11-q11.11)	X	
CEP12*	CEP12 (12p11.1)	X	
CEP17-Hydatidiform Mole			Mole*
CLL/SLL FISH PANEL*	Components: 11q22.3_ATM; 13q14_D13S25; 17p13.1_P53; CEP12 - IGH translocations; t(11;14) CCND1/IGH	X	
Copy Control 3 (CC3)*	CEP3 (3p11.1-q11.1)	X	
Copy Control 9 (CC9)*	CEP9 (9p11-q11)	X	
Copy Control 15 (CC15)*	CEP15 (15p11.1-q11.1)	X	
EGFR/CEP7			X
EGR1 (5q31/5p15.5) IVD*		X	
EWSR1 (22q12) translocations			X
FUS (16q11) translocations			X
HER2/CEP17 (PathVysion)*			X
Hydatidiform mole / molar pregnancy panel	Components: p57-Kip2 by IHC; Ki-67 by IHC; CEP17-Hydatidiform Mole FISH		Mole*
IGH translocations*	IGH (14q32)	X	X
inv16 / t(16;16)(p13;q22) (CBFB)*	CBFB	X	
MALT1 (18q21) translocations			X
MALT1 Breakapart (18q21) positive, reflex panel	Components: t(11;18) MALT1/API2; t(14;18) IGH/MALT1		X
MDM-2/SE12	MDM2		X
MDS (Myelodysplastic Syndrome) panel*	Components: 7q31/del 7q; EGR1 (5q31/5p15.5); 20q12; CEP8 (Trisomy 8)	X	
MET (7q31.2) / CC7	CMET, c-MET, hepatocyte growth factor receptor, HGFR		X
MYC (8q24) translocations*	c-MYC	X	X
MYC PANEL	Components: IGH translocations; MYC (8q24) translocations	X	
Myeloma FISH PANEL*	Components: 1q21+1p21; 13q14_D13S25; 17p13.1_P53; t(4;14) FGFR3/IGH; t(11;14), CCND1/IGH; t(14;16) IGH/MAF; CEP5; CEP7; CEP11; CC3; CC9; CC15; Algorithmic panel. Some tests may not apply	X	
Myeloproliferative Neoplasm (MPN) FISH panel*	Components: 13q14_D13S25 - 20q12 - CEP8- Copy Control 9 (CC9)	X	
Non Hodgkin Lymphoma (Agressive B-NHL) panel*	PANEL components: MYC (8q24) translocations - IGH translocations - t(14;18) IGH/BCL2 - BCL6 translocations	X	X
Non Hodgkin Lymphoma (Indolent B-NHL) panel*	Components: t(14;18) IGH/BCL2 - IGH translocations - BCL6 translocations - t(11;14) CCND1/IGH - MALT1 (18q21) translocations	X	X
P16 (CDKN2A/CC9)	CDKN2A/CC9		X
RARA translocations*	RARA (17q12)	X	X
RET (10q11.21) Breakapart			X
ROS-1 (16q22.1) translocations			X
SMS/RARA			X
SS18-SYT-synovial sarcoma-X18	SS18 (SYT-18q11.2)		X
t(4;14) FGFR3/IGH*	t(4;14)(p16;q32) (IGH/FGFR3)	X	X
t(8;21) (RUNX1/RUNX1T1)*		X	
t(9;22) BCR/ABL*	t(9;22)(q34;q11.2) (BCR/ABL)	X	X
t(11;14), CCND1/IGH*	t(11;14)(q13;q32) (IGH/CCND1)	X	X
t(11;18), MALT1/API2 (& MALT1/BIRC3)	t(11;18)(q21;q21) (API2/MALT1); t(11;18)(q21;q21) (BIRC3/MALT1)		X
t(14;16) IGH/MAF*	t(14;16)(q32;q23) (IGH/MAF)	X	X
t(14;18) IGH/BCL2*	t(14;18)(q32;q21) (IGH/BCL2)	X	X
t(14;18) IGH/MALT1	t(14;18)(q32;q21) MALT1		X
t(15;17) PML/RARA*	t(15;17)(q22;q21.1) (PML/RARA)	X	X
TOP2A/CEP17	TOP2A		X
TP53/CEP17	P53		X

* Available as tech only; please inquire.